Business
2026 RESULT OF ANNUAL GENERAL MEETING
ImmuPharma PLC announced the results of its Annual General Meeting, confirming that all six resolutions, including the re-appointment of Ketan Patel as director and Crowe UK LLP as auditor, were passed by shareholders with strong support, ranging from 93% to 99% of votes cast. The company also received shareholder approval for directors to allot shares and adopt new Articles of Association, with 152,641,450 shares (94%) voting in favour of the first share allotment resolution and 151,322,867 shares (93%) for the second special resolution. The total number of issued ordinary shares eligible to vote was 623,911,379. Disclaimer*
About this update from Immupharma Plc
RNS: RELEASE 25 June 2026 ImmuPharma PLC ("ImmuPharma" or the "Company") 2026 RESULT OF ANNUAL GENERAL MEETING ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that six of the six resolutions (Resolutions 1 - 6 inclusive) were duly passed by shareholders. Details are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year ended 31 December 2025 together with the reports thereon of the directors and auditors of the Company 163,496,678 99 2,252,180 1 365,965 2. To re-appoint Ketan Patel as a director of the Company 156,211,793 98 3,080,916 2 6,822,114 3. To re-appoint Crowe UK LLP as Auditor of the Company 163,482,368 99 2,311,240 1 321,215 4. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting 152,641,450 94 11,960,794 6 1,512,579 SPECIAL RESOLUTION 5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting 151,322,867 93 13,507,185 7 1,284,771 SPECIAL RESOLUTION 6. That, with effect from the conclusion of the Annual General Meeting, the draft Articles of Association be adopted as the Articles of Association of the Company in substitution for, and to the exclusion of, the Company's existing Articles of Association. 155,666,377 96 7,767,242 4 2,681,204 As at the date of the AGM, the number of issued ordinary shares of the Company was 623,911,379 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total. Ends For further information please contact: ImmuPharma PLC ( www.immupharma.com ) Tim McCarthy, Chief Executive Officer and Chairman Lisa Baderoon, Head of Investor Relations +44 (0) 207 206 2650 + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson +44 (0) 203 36 8 3550 +44 (0) 203 650 3650/51 +44 (0) 1483 413500 Notes to Editors About ImmuPharma PLC ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptidebased therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. For additional information about ImmuPharma please visit www.immupharma.co.uk ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.